Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: A systematic review and meta-analysis

Annals of Internal Medicine

Volumn 163, Issue 1, 2015, Pages 32-39

  Uthman, Olalekan A ^a   Okwundu, Charles ^b   Gbenga, Kayode ^c   Volmink, Jimmy ^b   Dowdy, David ^d   Zumla, Alimuddin ^e   Nachega, Jean B ^f  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Parran Hall 503   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUNG TUBERCULOSIS; META ANALYSIS; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THERAPY DELAY; TIME TO TREATMENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CAUSE OF DEATH; COMPLICATION; DRUG ADMINISTRATION; FEMALE; HIV INFECTIONS; IMMUNOLOGY; MALE; TUBERCULOSIS, PULMONARY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; TUBERCULOSIS, PULMONARY;

EID: 84937044550     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2979     Document Type: Review

References (34)

1. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-12. [PMID: 16868441]
2. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999;340:367-73. [PMID: 9929528]
3. Lucas SB, De Cock KM, Hounnou A, Peacock C, Diomande M, HondéM, et al. Contribution of tuberculosis to slim disease in Africa. BMJ. 1994;308:1531-3. [PMID: 7912597]
4. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet. 1995;345:607-10. [PMID: 7898177]
5. Perriëns JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332:779-84. [PMID: 7862181]
6. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000;24:23-9. [PMID: 10877491]
7. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367:926-37. [PMID: 16546541]
8. Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, et al; Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007;45: 1518-21. [PMID: 17990236]
9. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med. 2010;7:e1000296. [PMID: 20582324] doi:10.1371/journal.pmed.1000296
10. Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, Nachega JB, et al. Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis. AIDS Res Ther. 2013;10:19. [PMID: 23849301] doi:10.1186/1742-6405-10-19
11. Nachega JB, Rosenkranz B, Simon G, Chaisson RE, Diacon A, Taljaard J. Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. Infect Disord Drug Targets. 2011;11:134-43. [PMID: 21406051]
12. Nachega JB, Morroni C, Chaisson RE, Goliath R, Efron A, Ram M, et al. Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient Prefer Adherence. 2012;6: 887-91. [PMID: 23271897] doi:10.2147/PPA.S38897
13. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine-and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-9. [PMID: 18677025] doi:10.1001/jama.300.5.530
14. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14:1039-43. [PMID: 20032533] doi:10.3851/IMP1455
15. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS. 2010;5: 61-9. [PMID: 20046149] doi:10.1097/COH.0b013e3283339309
16. Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol. 2011;2011: 103917. [PMID: 21234380] doi:10.1155/2011/103917
17. Naidoo K, Baxter C, Abdool Karim SS. When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis. 2013; 26:35-42. [PMID: 23188213] doi:10.1097/QCO.0b013e32835ba8f9
18. Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14:563-71. [PMID: 24810491] doi:10.1016/S1473-3099(14)70733-9
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-58. [PMID: 12111919]
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
21. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11:22. [PMID: 21349195] doi:10.1186/1471-2288-11-22
22. Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52:1374-83. [PMID: 21596680] doi:10.1093/cid/cir230
23. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706. [PMID: 20181971] doi:10.1056/NEJMoa0905848
24. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment.NEngl J Med. 2011;365:1492-501. [PMID: 22010915] doi: 10.1056/NEJMoa1014181
25. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al; CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-81. [PMID: 22010913] doi:10.1056/NEJMoa1013911
26. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-91. [PMID: 22010914] doi:10.1056/NEJMoa1013607
27. Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, et al. Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts <200 cells/μL: TB-HAART study, a randomized clinical trial. PLoS One. 2015;10:e0122587. [PMID: 25966339] doi:10.1371/journal.pone.0122587
28. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, et al; TIME Study Team. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr. 2012;60:377-83. [PMID: 22592586] doi:10.1097/QAI.0b013e31825b5e06
29. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, et al. Early versus delayed initiation of antiretroviral therapy for Indian HIVInfected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012;12:168. [PMID: 22846195]
30. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415-30. [PMID: 21504399] doi:10.1586/eri.11.21
31. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298. [PMID: 17941716]
32. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa [Letter]. JAMA. 2008;300:506-7. [PMID: 18677022] doi:10.1001/jama.300.5.506
33. Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIVinfected patients on antiretroviral therapy in Africa. Trop Med Int Health. 2010;15 Suppl 1:63-9. [PMID: 20586962] doi:10.1111/j.1365-3156.2010.02507.x
34. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-23. [PMID: 18652998] doi:10.1016/S1473-3099(08)70184-1